Generative AI that models millions of molecular structures derived from rare fungi — discovering novel chemical pathways for next-generation antibiotics and specialized therapeutics.
We are just learning to read the language.
Fungi produce some of the most potent bioactive compounds known to science — penicillin, statins, immunosuppressants. But less than 5% of the estimated 5.1 million fungal species have been chemically characterized. Manual discovery is impossibly slow.
Our generative AI models millions of molecular structures derived from fungal genomes — predicting novel chemical pathways for antibiotics and specialized therapeutics. We identify compounds with high binding affinity, low toxicity, and feasible synthesis routes — then validate them in silico before your lab ever touches a petri dish.
Fungal genomics, transformed into pharmaceutical breakthroughs.
Variational autoencoders and transformers generate millions of novel molecular structures based on fungal biosynthetic gene clusters — exploring chemical space no human chemist could map.
Generative AIDeep learning models predict binding affinity to specific protein targets (bacterial ribosomes, viral proteases, cancer kinases) — prioritizing compounds most likely to succeed.
Molecular DockingAI evaluates synthetic accessibility — predicting viable chemical pathways and identifying required precursors, catalysts, and reaction conditions before lab synthesis begins.
RetrosynthesisMachine learning predicts absorption, distribution, metabolism, excretion, and toxicity — filtering out compounds likely to fail in clinical trials.
ADMET · SafetyMeasured results from labs using the platform.
Molecular structures modeled from fungal genomes
Novel compounds identified with therapeutic potential
Synthesis success rate for AI-predicted pathways
Faster discovery timeline vs. traditional screening
“Fungi have been evolving chemical defenses for 1.5 billion years. We’re just learning to read the language.”
Mycopharms empowers every stakeholder in the drug discovery ecosystem.
Accelerate antibiotic and therapeutic discovery with generative AI and in silico validation.
Build a pipeline of novel compounds without the cost of massive high-throughput screening.
Explore fungal chemical diversity for fundamental research and publication.
Offer AI-powered fungal compound discovery as a differentiated service to clients.
Trusted by leading pharmaceutical research teams worldwide.
Mycopharms identified a novel antibiotic scaffold from an obscure Penicillium species that our traditional screening missed entirely. It’s now our lead compound for MRSA.
We went from idea to validated lead compound in 6 months — a process that normally takes 3-4 years. The retrosynthesis AI is remarkably accurate.
The ADMET predictions saved us from pursuing dozens of dead-end compounds. We now prioritize only candidates with real clinical potential.
Mycologists, computational chemists, and AI researchers united to unlock nature’s pharmacy.

Mycologist and natural products chemist with 15+ years in fungal secondary metabolites.

AI/ML Ph.D. specializing in generative chemistry and molecular property prediction.

Molecular dynamics and docking expert. Built the binding prediction models behind Mycopharms.

Product leader with deep experience in scientific software and drug discovery platforms.
Tell us about your discovery goals, and we’ll show you how Mycopharms can help.
Deploy Mycopharms in your R&D workflow in days. Start exploring fungal chemical space with generative AI.
Provide your target protein, therapeutic area, and any known fungal genomes of interest.
Our AI models millions of molecular structures and predicts binding, synthesis, and safety.
Receive ranked lead compounds with synthesis routes — ready for lab validation.